News

Tech Startups Apply for Fall RAMP Cohort

RAMP is accepting applications are for their fall cohort to begin in September 2021.

RAMP is looking for technology startups with scalability, and coachable entrepreneurs who have a desire to do the work.

RAMP will select up to five companies for the 12-week cohort that provides:

• Expert 1:1 mentoring with the region’s top entrepreneurs and executives
• Free office space with high-speed internet in downtown Roanoke in Virginia’s Blue Ridge
• Access to venture capital
• $20,000 in equity-free funding

 

Application Close Date: August 15 Cohort

Start Date: September 13

DEMO DAY (tentative): December 9

Visit here to apply.

Recent News

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these